NASDAQ · TSBX
Healthcare · Biotechnology
$0.36
Up+$0.00 (+0.00%)
Updated Sep 18, 2026, 4:12 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
TSBX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning TSBX.
TSBX research
Company profile and research snapshot.
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 14, 2024 | B of A Securities | Neutral | — |
| Aug 19, 2024 | Piper Sandler | Overweight | — |
| Aug 19, 2024 | B of A Securities | Buy | — |
| Aug 15, 2023 | B of A Securities | Buy | — |
| Aug 15, 2023 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jul 5, 2025
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies undergoing sales or mergers.
GlobeNewswire Inc. · Jun 30, 2025
Class action attorney Juan Monteverde is investigating the merger of Turnstone Biologics Corp. with XOMA Royalty Corporation, where shareholders will receive $0.34 in cash per share and a contingent value right.
GlobeNewswire Inc. · May 13, 2024
Turnstone Biologics Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
GlobeNewswire Inc. · Mar 21, 2024
Turnstone reports fourth quarter and full year 2023 financial results and provides recent business highlights.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TSBX.
No results
No recent SID articles mention TSBX.
